enVVeno Medical Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$15.7MTTM through 30 Jun 2026
Free Cash Flow -$14.6MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-76.1%ROE
-69.4%ROA
Balance Sheet Health
Debt / Equity0.03x
Current Ratio11.89x
Net Debt-$24.9Mnet cash position
Cash & Equivalents$2.8M
Quality Metrics
Altman Z-Score-10.51
Piotroski F-Score2 / 9
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2019: $31.2K
Diluted EPS-$24.97TTMFY2025: $-33.06
Dividend
No dividend
Capital Allocation
R&D Spend$8.7M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical Device Development | $0 | View detailsThe company is strategically pivoting from the surgical VenoValve to the minimally invasive, transcatheter enVVe System, with patient enrollment expected to commence in late 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.